Literature DB >> 11793432

Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT 2000 cyclosporine specific assay with the COBAS MIRA-plus analyzer.

S Kimura1, S Iyama, Y Yamaguchi, Y Kanakura.   

Abstract

We describe the evaluation of the EMIT 2000 cyclosporine specific assay kit, an enzyme-multiplied immunoassay for cyclosporine in whole blood, with a COBAS MIRA-plus analyzer. The enzyme used for the assay was glucose-6-phosphate dehydrogenase (EC 1.1.1.49 G6PDH) from Leuconostoc mesenteroides; the monoclonal antibody is fairly specific for cyclosporine, and is not reactive with most metabolites. The assay principle is based on competitive immunoassay with G6PDH-labeled cyclosporine and cyclosporine in sample to the anticyclosporine mouse monoclonal antibody binding site. The within-assay coefficient of variation (CV) of this method was 2.7-4.2% (n = 10) at the levels of 56.2-339.7 microg/L. Day-to-day CVs ranged from 4.2-8.1% at the levels of 47.2-350.2 microg/L. The within-day CVs ranged from 2.0-6.4% at the levels of 43.3-330.5 microg/L. The functional detection limit was 24.9 microg/L. Samples treated with pretreatment reagent were stable at least 5 hr. Calibration was stable at least 10 days. The analytical recovery was 81-109%. The correlation between values obtained with the EMIT 2000 cyclosporine specific assay kit (y) and fluorescence polarization immunoassay (FPIA) (TDxFLx) (x) was: y = 0.880x - 13.053 microg/L (r = 0.984, Sy/x = 15.968, n = 71) with a mean difference of 31.42 +/- 19.89 microg/L ((TDxFLx - EMIT 2000) +/- SD); for the FPIA (AxSYM) (x): y = 0.989 - 4.144 microg/L (r = 0.981, Sy/x = 17.478, n = 71) with a mean difference of 5.56 +/- 17.38 microg/L ((AxSYM - EMIT 2000) +/- SD); and for the radioimmunoassay (RIA, CYCLO-Trac SP) (x): y = 0.893 - 6.764 microg/L (r = 0.993, Sy/x = 10.582, n = 71) with a mean difference of 22.18 +/- 14.98 microg/L ((RIA - EMIT 2000) +/- SD) using the Bland-Altman technique. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11793432      PMCID: PMC6807697          DOI: 10.1002/jcla.1044

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  12 in total

Review 1.  Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them.

Authors:  L M Shaw; B Kaplan; D Kaufman
Journal:  Clin Chem       Date:  1996-08       Impact factor: 8.327

2.  Cross-reactivity of cyclosporine metabolites in two different radioimmunoassays in which the same specific monoclonal antibody is used.

Authors:  P E Wallemacq; S C Lee; G Lhoëst; A Hassoun
Journal:  Clin Chem       Date:  1990-02       Impact factor: 8.327

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood.

Authors:  R W Yatscoff; K R Copeland; C J Faraci
Journal:  Clin Chem       Date:  1990-11       Impact factor: 8.327

5.  Measurement of cyclosporine A by a specific radioimmunoassay with a monoclonal antibody and 125I tracer.

Authors:  S C Lee; A M Brudzinski; J L Yasmineh; N J Johanson; I A Ferber; L K Maas; P Y Wong; P A Keown; J W Orf
Journal:  Clin Biochem       Date:  1991-02       Impact factor: 3.281

6.  Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific?

Authors:  W Steimer
Journal:  Clin Chem       Date:  1999-03       Impact factor: 8.327

7.  The EMIT Cyclosporine Assay: development of application protocols for the Boehringer Mannheim Hitachi 911 and 917 analyzers.

Authors:  V C Dias; D F Legatt; R W Yatscoff
Journal:  Clin Biochem       Date:  1997-03       Impact factor: 3.281

8.  Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation.

Authors:  J M Kovarik; L Vernillet; E A Mueller; R Freiburghaus; W Niederberger; K Kutz
Journal:  Ther Drug Monit       Date:  1994-10       Impact factor: 3.681

9.  Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC.

Authors:  E Schütz; D Svinarov; M Shipkova; P D Niedmann; V W Armstrong; E Wieland; M Oellerich
Journal:  Clin Chem       Date:  1998-10       Impact factor: 8.327

Review 10.  Cyclosporin A. Clinical pharmacology and therapeutic potential.

Authors:  D J White
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

View more
  2 in total

1.  Immunoassay Methods and their Applications in Pharmaceutical Analysis: Basic Methodology and Recent Advances.

Authors:  Ibrahim A Darwish
Journal:  Int J Biomed Sci       Date:  2006-09

Review 2.  Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine.

Authors:  Vanessa P Gaspar; Sahar Ibrahim; René P Zahedi; Christoph H Borchers
Journal:  J Mass Spectrom       Date:  2021-11-04       Impact factor: 1.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.